Laevolac

Lactulose, the active ingredient in Laevolac, is an osmotic laxative presented as a liquid solution for oral use. It is employed to soften stools in constipation and to reduce ammonia absorption in patients at risk of hepatic encephalopathy. It is widely used in adult and pediatric populations under medical supervision.

GNH USA supplies Laevolac as a licensed, GDP‑compliant international pharmaceutical supplier, sourcing the product from EU markets and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All shipments adhere to stringent quality standards and regulatory requirements.

Lactulose, an osmotic laxative, is used to manage conditions related to bowel motility and hepatic ammonia accumulation. - Constipation: softens stools and promotes regular bowel movements. - Hepatic encephalopathy: lowers colonic ammonia production, helping to prevent or treat episodes in patients with liver disease. - Hyperammonemia: reduces blood ammonia levels in individuals with liver dysfunction.

Lactulose may cause a range of gastrointestinal and metabolic reactions, most of which are mild and transient. Common Side Effects: - Abdominal bloating - Diarrhea - Flatulence - Nausea Serious or Rare Side Effects: - Severe electrolyte imbalance - Dehydration - Allergic reaction (rash, itching)

When using Laevolac, consider the following safety measures. - Dose titration: start with the lowest effective volume and adjust based on stool response. - Fluid intake: maintain adequate hydration to prevent dehydration. - Electrolyte monitoring: check serum electrolytes in patients with renal or cardiac disease. - Avoid in complete bowel obstruction: risk of perforation. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lactulose can interact with several medicines; awareness helps maintain efficacy and safety. Major Interactions (Avoid): - Antibiotics (e.g., rifaximin): may reduce lactulose fermentation, diminishing efficacy. - Laxatives (e.g., senna): additive laxative effect, risk of diarrhea. Moderate Interactions (Monitor Closely): - Diuretics: increased risk of electrolyte disturbances. - Mineral supplements (e.g., calcium, magnesium): may bind lactulose, reducing effect. - Insulin or oral hypoglycemics: lactulose can affect glucose absorption, monitor blood sugar.